Opendata, web and dolomites


OUTLIVE: a disruptive non-invasive ultrasound therapy to treat all patients affected with aortic stenosis.

Total Cost €


EC-Contrib. €






 OUTLIVE project word cloud

Explore the words cloud of the OUTLIVE project. It provides you a very rough idea of what is the project "OUTLIVE" about.

imaging    safety    medtech    business    function    untreated    opening    2030    solution    revenues    unmet    solutions    accelerate    efficacy    prize    jobs    valve    dramatically    gold    scalable    cumulative    complications    age    market    death    sick    patients    25    institut    standard    ce    stenosis    combined    contests    hegp    therapy    commercialisation    physicians    perfusion    valvosoft    treatment    establishments    refine    french    langevin    relation    calcifies    repair    delivers    sudden    care    created    stiffens    ultrasound    leader    plan    world    exceeding    outlive    disease    winner    heart    replacing    1bn    trust    risks    guided    cardiologists    blood    innovative    body    time    benefit    narrowing    poor    demonstrated    health    ultrasounds    clinical    caused    expertise    life    mark    aortic    device    immense    entrepreneur    changer    investor    hospital    treating    cardiawave    invasive    causes    strategy    intensity    date    context    revolutionary    million    risk    ready    game    medical    image    adopters    threatening    gateway    unlike    thanks    consists   

Project "OUTLIVE" data sheet

The following table provides information about the project.


Organization address
city: PARIS
postcode: 75017
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙563˙750 €
 EC max contribution 2˙494˙625 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARDIAWAVE FR (PARIS) coordinator 2˙494˙625.00


 Project objective

Aortic stenosis (AS) is a life-threatening disease caused by the narrowing of the opening of the aortic valve which is the “gateway” from the heart to the body. With age, the aortic valve calcifies and stiffens, leading to poor blood perfusion. It causes heart failure and sudden death. The only medical response to date consists in replacing the aortic valve. It is provided to very sick patients at high risk of sudden death, who represents 25% of all AS patients (6 million in Europe and US). All other affected patients remain untreated. It is an immense unmet medical need. In this context, French medtech Cardiawave has developed a revolutionary solution: Valvosoft, a very innovative real-time image guided medical device for the non-invasive treatment of all AS patients. The device delivers focused high-intensity ultrasounds which repair the aortic valve function. Unlike the current medical solutions, Valvosoft is a non-invasive treatment with low risks, complications and costs. It is a game-changer for patients, physicians and health care establishments because it dramatically changes the way of treating AS throughout the world. It should become a new gold standard: every AS patients will benefit from Valvosoft. Prize-winner of many contests, Cardiawave was created thanks to the combined expertise of an entrepreneur, the Institut Langevin, world leader in ultrasound imaging & therapy and cardiologists from HEGP hospital. The OUTLIVE project will allow Cardiawave to refine current go-to-market strategy and develop an investor ready business plan following CE-mark. Valvosoft clinical safety and efficacy will be demonstrated and reliable trust relation with early-adopters will be established. OUTLIVE will accelerate the scalable Valvosoft commercialisation and enable Cardiawave to become the future leader in non-invasive therapy with expected cumulative revenues exceeding €1.1bn by 2030 and more than 100 new European jobs created.


year authors and title journal last update
List of publications.
2019 D. Suarez Escudero, M. Tanter, M. Pernot
published pages: , ISSN: , DOI:
2019 M. Pernot, M. C. Rémond, R. Penot, D. Ladarré, Philippe Mateo, N. Ialy-Radio, D. Suarez, Guillaume Goudot, Wojciech Kwiecinski, Michael Vion, F. Betting, Aurélien Corbel, Ana Fouquier, Sergio Cammarata, Eric Noël, Zahir Larabi, M. Tanter, E. Messas
A new therapeutic device for transthoracic treatment of calcified aortic stenosis
published pages: , ISSN: , DOI:

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OUTLIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OUTLIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

HUD (2018)


Read More